Core Viewpoint - Jichuan Pharmaceutical's Q2 revenue decreased by 25.03% year-on-year to 1.223 billion yuan, primarily due to a high base effect from the previous year in the respiratory product category [1] - The company reported a net profit attributable to shareholders of 284 million yuan, down 42.39% year-on-year, and a net profit excluding non-recurring items of 228 million yuan, down 49.70% year-on-year, indicating significant pressure on profitability due to declining terminal demand for core products [1] - The company expects a recovery in demand for respiratory products in the second half of the year, supported by the seasonal increase in respiratory diseases, and will continue to focus on the development and launch of new products [1] Financial Performance - Q2 revenue was 1.223 billion yuan, a decline of 25.03% year-on-year [1] - Net profit attributable to shareholders was 284 million yuan, a decrease of 42.39% year-on-year [1] - Net profit excluding non-recurring items was 228 million yuan, down 49.70% year-on-year [1] Market Outlook - The company anticipates a recovery in terminal sales in the second half of the year as inventory levels for core respiratory products have returned to reasonable levels [1] - The upcoming high season for respiratory diseases is expected to boost demand [1] - Continuous progress in the research and development of new product pipelines is a focus for the company [1]